Medios AG, a leading provider of Specialty Pharma in Europe, announced the appointment of Katrin Neuffer as Director Investor Relations & Communications, effective immediately. Neuffer, who holds a degree in business administration, brings nearly 20 years of experience in capital markets communications, having previously served as Head of Investor Relations & Corporate Communications at Wacker Neuson SE and as Vice President at Exyte Group. Her appointment marks a strategic move for Medios as it seeks to enhance its presence in the capital markets and foster stronger relationships with investors, analysts, and the media.
Neuffer succeeds Claudia Nickolaus, who has played a pivotal role in shaping Medios' investor relations activities since its early days. Nickolaus contributed significantly to the company's financial reporting, ESG communications, and the organization of its first Capital Markets Day in 2022. Thomas Meier, CEO of Medios AG, expressed gratitude for Nickolaus’ dedication and professionalism, acknowledging her role in building the company's investor relations foundation.
In her new role, Neuffer will oversee communications with investors, analysts, and the public. Her extensive background includes guiding companies through IPOs and strategic repositioning, which will be instrumental as Medios aims to strengthen its market standing. Notably, she previously led the preparation of an IPO at Exyte Group with a target market capitalization exceeding EUR 2 billion. Since 2020, she has worked as an independent consultant, focusing on investor relations, IPO preparation, and crisis communications.
The appointment comes at a critical time for Medios, with several key events scheduled in the 2026 financial year. The company will release its Half-Year Financial Report on August 12, participate in the Berenberg and Goldman Sachs 15th German Corporate Conference in September, hold its Capital Markets Day on September 28/29, and publish its quarterly statement on November 10. These events underscore the importance of effective communication with the financial community, and Neuffer's expertise will be crucial in ensuring that Medios effectively conveys its strategic vision and performance.
Medios AG is Germany's first listed specialty pharmaceutical company and operates across Germany, the Netherlands, Belgium, and Spain. The company focuses on individualized medicine, aiming to make innovative therapies accessible through collaborations with pharmacies, specialist practices, and pharmaceutical companies. Its shares are listed on the Frankfurt Stock Exchange's Prime Standard and included in the SDAX index. As Medios continues to expand its footprint in the specialty pharma sector, the appointment of a seasoned investor relations professional like Neuffer signals a commitment to transparent and effective communication, which is vital for maintaining investor confidence and supporting long-term growth.
For more information about Medios AG and its initiatives, visit the company's website at [www.medios.group](http://www.medios.group) and learn about individualized medicine at [https://app.medios.group/en/individualizedmedicine](https://app.medios.group/en/individualizedmedicine).
